skip to content
Advertisement
Premium

Aman Gupta refuses Shark Tank India pitchers’ Shilajit-based product, Vineeta Singh says they’re losing money with each sale

In the latest episode of Shark Tank India, a company selling Shilajit walked in to get a sizeable investment, but didn't quite impress the sharks with their performance

Namita Thapar and Aman Gupta on Shark tank IndiaNamita Thapar and Aman Gupta make point out major concerns with Shilajit company on Shark tank India

Considering India is the most populated country in the world, it is ironic that sexual health discussions are still seen as taboo topics. Probably why, in the latest episode of Shark Tank India 4, Zinga Vita’s pitch about their Ayurveda company didn’t just make the ‘sharks’ smile and laugh, but also gave a lot of points to ponder.

Chandigarh-based Dheeraj Nagpal and Sachin Goel’s Zinga Vita makes multiple products based on the ayurvedic supplement, Shilajit. Arguing that sexual wellness isn’t the only benefit of Shilajit, the team said that it improves metabolism, and can be used by men and women. With a firm focus on removing the taboo from Shilajit, the entrepreneurs asked for Rs 1 crore for 1.25% equity at a valuation of Rs 80 crore during their Shark Tank India pitch.

ALSO READ: Namita Thapar wonders if women’s safety tool will harm the attacker, asks Shark Tank India founder: ‘In terms of hospitalisation…’

Story continues below this ad

When asked by the entrepreneurs to try their product, Aman Gupta, quickly replied with a huge smile plastered on his face, “I don’t need Shilajit… What are you even talking?” This lightened the room up as questions started flying from all over about why they think a product that has been in the market for so many years together would need a facelift of sorts.

The owners responded with claims of increased awareness in India, and a demand in the US for the product, which claims increased strength, improved vitality, and muscle gain. Vineeta didn’t waste a moment before asking if these claims were made after a new study since Shilajit has always been known for erectile dysfunction issue. However, Dheeraj immediately said that what the herb essentially does is that it improves metabolism, and produces energy, which can be positioned in many ways, including sexual health and muscle gain.

But what really tipped the scales against them were the lack of clinical trials to test the efficacy of their product, and their ambition. While Namita drilled home the necessity of doing trials, Aman was quite flabbergasted about their product returns. Even explanations that the market would correct itself after the taboo clears didn’t move the sharks, and Aman said he was out of the deal because there was no control in the burns or the RTOs. “Focus on fundamentals, and base it on evidence,” pointed out Namita, who said that lack of trials even if there was a proper quality management check in place, was concerning.

ALSO READ:  Shark Tank India 4 pitcher Ashima Batra reacts to netizens saying Anupam Mittal ‘invests in pretty girls’: ‘My life would be far easier if that were all it took’

Story continues below this ad

With every other shark including Ritesh, who felt it was too early to decide if it had a strong customer base or is it just a fad, Vineeta, who questioned the increasing investment in the marketing cost and losing more money with every sale they make, and Kunal Bahl, who asked them to get back to the drawing board, and decide on cost-cutting and profitability before scaling up, bowing out of the deal, Zinga Vita left the show without getting the sharks to invest in their dream.

Click here to follow Screen Digital on YouTube and stay updated with the latest from the world of cinema.

Latest Comment
Post Comment
Read Comments
Advertisement
Advertisement
Advertisement
Advertisement